A medical worker at Parrish Medical Center holds a vial of Modern COVID-19 vaccine in a vehicle through the vaccination clinic for Port Canaveral employees, workers at local hotels and restaurants, and Port community residents Canaveral.
Paul Hennessy | LightRocket | Getty Images
Modern said its Covid-19 vaccination shot produced a “robust” antibody response against the highly contagious delta variant, according to details of a study published Thursday with the company’s second-quarter earnings report .
In a second-phase trial, Moderna tested a 50-microgram dose of three vaccine-boosting candidates in previously vaccinated individuals. Reinforcement shots produced a promising immune response against three variants, including delta, with antibody levels approaching those seen in unvaccinated people who received two doses of 100 micrograms, he said. company.
The data was sent to a peer-reviewed journal for publication, he said.
The company’s second-quarter financial results also exceeded Wall Street’s expectations on earnings and revenues. Here’s how Moderna compared it to what Wall Street predicts, according to average estimates compiled by Refinitiv:
- EPS: $ 6.46 per part versus $ 5.96 per expected part
- Revenue: $ 4.35 billion versus the estimated $ 4.2 billion
New data on boosters comes as the delta variant spreads to several countries, including the United States. The Centers for Disease Control and Prevention has said the variant is as contagious as chickenpox and can make elderly people sick, even if they have been completely vaccinated.
In the slides that accompanied Thursday’s earnings report, Moderna said she expects the variant to lead to an increase in advanced infections, which occur in vaccinated individuals.
“While we see the long-term effectiveness of Phase 3 through 6 months, we expect that neutralizing titers will continue to decline and eventually impact the effectiveness of the vaccines,” the company wrote. “After this intersection, we believe the 3-dose booster will probably be needed before the winter season.”
People in the United States have already found ways to secure reinforcements amid concerns about delta. However, the World Health Organization on Wednesday called on rich nations to stop the distribution of Covid reinforcement vaccines, citing vaccine inequities around the world.
Moderna also said Thursday that a final analysis of its third-phase study found that the two-dose vaccine was 93% effective, with the effectiveness remaining “lasting” for six months after the administration of the second dose.
In comparison, Pfizer and BioNTech reported that their vaccination effectiveness dropped to about 84% six months after the second stroke.
Moderna, which was founded in 2010, was the second company to obtain US authorization for its Covid vaccine behind Pfizer-BioNTech. Modern’s Covid vaccine generated $ 4.2 billion in sales in the three months ended June 30, according to the earnings report.
The company said it aims to produce between 800 million to 1 billion doses of Covid vaccine this year. It has signed vaccination contracts worth $ 20 billion in sales this year and has agreements worth $ 12 billion in 2022.